Rated avoid: losses widening, about 5.6% dilution, and in a downtrend.
Thesis (avoid, position, conviction 38)
Thesis carried over from the 2026-10-13 run.
Bull: Revenue is reaccelerating: Q2 2026 revenue of $18.7M grew 42% YoY (F-MRAM-1), and management guided Q3 2026 revenue to $19.5-20.5M (F-MRAM-7), above full-year 2025's $55.2M pace (F-MRAM-6). Balance sheet remains solid with $43.9M cash versus a small-cap market value (F-MRAM-4). Maxim Group initiated coverage with a Buy and a $25 price target, implying significant upside from the current $15.08 close. RSI14 at 36.7 is approaching oversold territory, and the stock is only modestly below its moving averages, so a reversion bounce is plausible if Q3 earnings (expected 2026-11-11) beat the raised guidance.
Bear: Despite revenue growth, profitability is deteriorating: GAAP net loss widened to $3.59M ($0.15/share) from $0.67M ($0.03/share) a year earlier (F-MRAM-3), and Q3 guidance still calls for a net loss of $0.05-0.10/share (F-MRAM-7) — growth is not yet converting to earnings. Share count rose from 22.98M to 24.27M in six months (F-MRAM-5), a ~5.6% dilution that works against per-share value even as revenue grows. Price action is unambiguously negative: MRAM trades below its 20-, 50-, and 200-day moving averages (F-MRAM-8), is down 8% over three months with three-month relative strength versus SPY of -11.4% (F-MRAM-9), and is 65.7% off its 52-week high — a stock genuinely in a technical downtrend despite a positive 12-month return. A VP of Sales sold shares on October 2, 2026 at $19.08, well above the current price (F-MRAM-10); while labeled a tax sale, it adds to a mixed insider/market signal context ahead of earnings on 2026-11-11, a binary event with an already-widening loss trend working against the name.
Valuation: The brief lacks P/E, EV/EBITDA, or FCF yield data, so a direct multiple-based valuation isn't possible. What is available shows revenue growth (+42% YoY) outpacing profitability, with GAAP losses widening and share dilution occurring — a combination that typically argues for a lower, not higher, multiple until losses narrow. The $25 sell-side target implies ~66% upside from $15.08, but that view is not corroborated by the brief with underlying fundamental detail (margins, path to profitability), so it should be weighted cautiously against the deteriorating loss trend and negative technical backdrop.
Catalysts
2026-11-11: Q3 2026 earnings release; consensus estimates imply EPS of $0.1258 and revenue of $20.502M versus guidance of $19.5-20.5M revenue and -$0.05 to -$0.10 GAAP EPS
Facts
F-MRAM-1: Revenue for the quarter ended June 30, 2026 was $18.736 million, compared with $13.201 million in the year-earlier quarter. (as of 2026-08-05)[E5503]source
F-MRAM-2: For the quarter ended June 30, 2026, product sales were $15.313 million and licensing, royalty, engineering services and other revenue were $3.423 million. (as of 2026-08-05)[E5504]source
F-MRAM-3: For the quarter ended June 30, 2026, Everspin reported a GAAP net loss of $3.589 million, or $0.15 per diluted share, compared with a $0.670 million net loss, or $0.03 per diluted share, a year earlier. (as of 2026-08-05)[E5503, E5504]sourcesource
F-MRAM-4: Cash and cash equivalents were $43.896 million at June 30, 2026, compared with $44.450 million at December 31, 2025. (as of 2026-06-30)[E5504]source
F-MRAM-5: Common shares issued and outstanding were 24,271,438 at June 30, 2026, compared with 22,977,797 at December 31, 2025. (as of 2026-06-30)[E5504]source
F-MRAM-6: For calendar 2025, revenue was $55.202 million, operating income was negative $6.508 million, and net income was negative $0.586 million. (as of 2025-12-31)[E5501]
F-MRAM-7: On August 5, 2026, Everspin forecast third-quarter 2026 revenue of $19.5 million to $20.5 million and GAAP net loss per share of $0.10 to $0.05. (as of 2026-08-05)[E5503]source
F-MRAM-8: The October 13, 2026 close was $15.08, below the 20-, 50- and 200-day moving averages of $17.10, $16.86 and $16.59, respectively. (as of 2026-10-13)[E4999]
F-MRAM-9: As of October 13, 2026, the stock's 12-month return was 42.13%, while its three-month relative strength versus SPY was negative 11.38%. (as of 2026-10-13)[E4999]
F-MRAM-10: A news report said VP of Sales Sean Dougherty sold 7,691 shares on October 2, 2026, at $19.08 per share, describing the sale as for taxes. (as of 2026-10-12)[E5008]source
What would change the view
A daily close back above the 50-day moving average of $16.86 on above-average volume
Q3 2026 results (due ~2026-11-11) showing a narrower GAAP net loss than the -$0.05 to -$0.10/share guidance with gross margin improvement
RSI14 dropping below 30 followed by a reversal candle, suggesting an oversold bounce setup with defined risk
Evidence that recent share issuance was tied to a specific strategic use (e.g., offering proceeds funding profitable capacity) rather than dilutive financing
Data quality
Quality score 96/100.
Gap: The quote block is timestamped October 14, 2026, after the supplied as-of date of October 13, 2026, so it was not used for price facts.
Gap: The November 11, 2026 earnings date is an estimate and may change.
Red flag: The GAAP net loss widened in the second quarter of 2026 compared with the year-earlier quarter.
Red flag: Common shares issued and outstanding increased between December 31, 2025 and June 30, 2026.
Red flag: A news report described a VP of Sales share sale on October 2, 2026; it said the sale was for taxes.